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Serous uterine endometrial cancer is a 
lethal disease for which new therapeutic 
regimens are urgently needed. 
Combinations of chemotherapeutic 
agents and small molecule growth factor 
inhibitors have demonstrated activity in 
cancers from other sites. Our objective 
was to determine whether such a 
combination could be active in serous 
endometrial cancer cells. The effects of 
the EGFR inhibitor gefitinib (ZD1839, 
Iressa) alone, paclitaxel alone, and the 
combination of both agents on the cell 
cycle and on cell proliferation were 
studied using Hec50co cells, a validated 
model for type II serous endometrial 
cancer with absent p53. First, we 
established the IC50 for paclitaxel alone 
(14 nM) compared to that of paclitaxel 
and gefitinib in combination (1.3 nM). 
This 10-fold reduction in the IC50 with 
dual therapy yielded a combination 
index of 0.25, strongly suggesting that 
the paclitaxel and gefitinib combination 
resulted in synergistic growth inhibition. 
Sixty-seven percent of the cells treated 
with paclitaxel and gefitinib arrested in 
the G2/M phase. This arrest of the cell 
cycle at G2/M with combination therapy 
was significantly greater than with single 
agent treatment alone (p < 0.001) and 
was associated with inhibition of p38 
phosphorylation and the induction of 
CDC25C phosphatase and Cyclin B1. 
When induced, these factors abrogate 
the G2/M checkpoint and result in rapid, 
premature progression to M phase; this 
mechanism is particularly active in the 
setting of absent p53. With rapid 
progression into M, the cells were highly 
sensitive to paclitaxel and were killed by 
the mechanism of mitotic catastrophe. 
Similar findings were observed in the 
same cells treated with the combination 
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of paclitaxel and a specific inhibitor of 
p38, SB203580. Our study suggests 
that inhibition of EGFR or downstream 
p38 pathway can abrogate the mitotic 
stress checkpoint induced by cytotoxic 
agents targeting microtubules such as 
paclitaxel. These findings suggest a new 
therapeutic strategy for the treatment of 
serous endometrial carcinoma worthy of 
clinical confirmation. 
 
